Eupraxia Pharmaceuticals Inc Ordinary Shares EPRX 深 沪
等待开盘 08-20 09:30:00 美东时间
5.39
+0.090
+1.70%
华盛通- 最 高5.42
- 今 开5.24
- 成交量 1.03万股
- 最 低 5.22
- 昨 收 5.30
- 总市值 1.93亿
- 52周最高 6.1999
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 2.20
- 委 比 -99.83%
- 总股本 3584.94万
- 历史最高 6.1999
- 量 比 1.35
- 振 幅 3.77%
- 历史最低 2.20
- 每 手 1
- 风险率 0.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.19) by 36.84 percent. This is a 52.94 percent decrease over losses of $(0.17) per
08-13 06:03
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Eupraxia Pharmaceuticals announced the dosing of the first patient in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial, targeting eosinophilic esophagitis (EoE). Positive data from the Phase 1b/2a trial, showing sustained outcomes in three patients after nine months, supports EP-104GI's potential. Additional data and top-line results are expected in October 2025 and H2 2026, respectively. The company reported a net loss of $8...
08-12 20:25
Cantor Fitzgerald Initiates Coverage On Eupraxia Pharmaceuticals with Overweight Rating, Announces Price Target of $11
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight rating and announces Price Target of $11.
07-24 19:08
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals has initiated the Phase 2b portion of the RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). The first patient has been dosed in this randomized, placebo-controlled study, which aims to evaluate the efficacy and safety of EP-104GI. The trial will enroll at least 60 patients across 25 global sites, with three dose arms: two active doses and one placebo. Data collection will include tissue health me...
07-08 11:00
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
HC Wainwright & Co. Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $12.
06-26 19:33
Canaccord Genuity Initiates Coverage On Eupraxia Pharmaceuticals with Speculative Buy Rating, Announces Price Target of C$9
Canaccord Genuity analyst Tania Armstrong-Whitworth initiates coverage on Eupraxia Pharmaceuticals (TSX:EPRX) with a Speculative Buy rating and announces Price Target of C$9.
06-16 23:36
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
Eupraxia Pharmaceuticals Inc. announced the successful outcome of its Annual General and Special Meeting of Shareholders held on June 2, 2025. All six nominees for the Board of Directors were elected, with strong shareholder support. Additionally, shareholders approved the re-appointment of auditors, the 2025 Omnibus Incentive Plan, and the re-pricing of certain stock options. Eupraxia, leveraging its DiffuSphere™ technology, focuses on developin...
06-02 22:30
Eupraxia Pharmaceuticals Reports Positive Nine-Month Outcomes in EoE Trial
Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. Eupraxia Pharmac...
05-05 19:55
Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
In a report released today, Gary Nachman from Raymond James maintained a Buy ra...
03-24 19:55
